• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Abbott expects COVID testing demand to remain strong, Biden orders insurance coverage

Abbott expects COVID testing demand to remain strong, Biden orders insurance coverage

January 11, 2022 By Sean Whooley

Abbott's BinaxNow COVID-19 Ag Card COVID-19 corona virus
Abbott’s BinaxNow COVID-19 Ag Card [Image courtesy of Abbott]
Abbott (NYSE:ABT) Chair & CEO Robert B. Ford has emphasized the importance of COVID-19 testing amid the ongoing omicron variant surge.

Today at the 40th Annual J.P. Morgan Healthcare Conference, Ford highlighted the role testing will play as Abbott’s BinaxNow rapid antigen test and other over-the-counter testing options remain in high demand.

The need for tests is significant enough that the Biden administration has ordered for eight over-the-counter COVID-19 tests per month to be covered by insurance.

“It was clear maybe because of that full-year 2020 that people really wanted to kind of believe that the silver bullet — the vaccine — will clear it all up,” Ford said, as transcribed by SeekingAlpha. “And I think it took [the delta variant of COVID-19] for us to ultimately realize that there is no silver bullet and that you have to have vaccines, therapeutics and testing.”

Ford said Abbott established a “leadership position” with COVID-19 testing, having a PCR system for lab-based testing and the popular BinaxNow rapid antigen test, for which the company foresaw sustainability and currently manufactures well over 100 million tests per month.

“We all saw this Thanksgiving, Christmas, a very big surge in testing, both on symptomatic testing and in PCR, and you see it in our rapid molecular testing also, the use of those technologies to be able to kind of do rapid diagnosing,” Ford said. “And then on the screening side with the rapid antigen test, there’s also a big, big demand also there. So [it’s a] big surge, whether it’s here in the U.S. or internationally, a very strong surge again also for both diagnosing and screening.”

Ford said forecasting the continued demand for testing is difficult, but the company maintains the capacity to support both U.S. and international demand.

The coming weeks will help the company better understand how to guide for 2022 and plan for when testing may eventually ramp down, but a portion will need to be sustained.

“An interesting kind of strategic play for us is to use the portfolio of products that we have and really kind of start to build a more sustainable rapid point-of-care, rapid diagnostic business not only that goes straight to the consumer, but also into other channels outside of the four walls of the hospital,” Ford said. “Abbott’s working is non-stop. We’ve got a lot of capacity. We’ve obviously had a pretty strong last couple of months of testing, and we expect that to continue here in the more immediate future.”

Filed Under: Business/Financial News, Diagnostics, Featured, Genomics/Molecular Diagnostics, News Well Tagged With: Abbott, coronavirus, COVID-19

More recent news

  • Medtronic escapes $106.5M payment in Colibri TAVR patent suit after court overturns jury verdict
  • RadNet closes iCAD acquisition, expands AI breast‑imaging portfolio
  • Hyperfine reports first commercial sales of next-gen AI-powered Swoop
  • Stereotaxis announces $12.5M offering
  • Nuwellis ends clinical trial of its ultrafiltration tech for heart failure

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy